Flood Watch
from SAT 11:00 PM MST until MON 5:00 AM MST, North Phoenix/Glendale, Aguila Valley, Mazatzal Mountains, Tonopah Desert, Gila Bend, San Carlos, East Valley, Northwest Pinal County, Northwest Valley, Southeast Valley/Queen Creek, Globe/Miami, Deer Valley, Fountain Hills/East Mesa, Apache Junction/Gold Canyon, Buckeye/Avondale, Tonto Basin, Rio Verde/Salt River, South Mountain/Ahwatukee, Dripping Springs, Southeast Gila County, Pinal/Superstition Mountains, Scottsdale/Paradise Valley, New River Mesa, Sonoran Desert Natl Monument, West Pinal County, Superior, Cave Creek/New River, Central Phoenix, Northwest Plateau, Eastern Cochise County below 5000 ft including Douglas/Wilcox, Upper Gila River and Aravaipa Valleys including Clifton/Safford, Southeast Pinal County including Kearny/Mammoth/Oracle, Western Pima County including Ajo/Organ Pipe Cactus National Monument, Dragoon/Mule/Huachuca and Santa Rita Mountains including Bisbee/Canelo Hills/Madera Canyon, Tucson Metro Area including Tucson/Green Valley/Marana/Vail, Tohono O'odham Nation including Sells, Baboquivari Mountains including Kitt Peak, Upper San Pedro River Valley including Sierra Vista/Benson, Chiricahua Mountains including Chiricahua National Monument, Galiuro and Pinaleno Mountains including Mount Graham, Santa Catalina and Rincon Mountains including Mount Lemmon/Summerhaven, White Mountains of Graham and Greenlee Counties including Hannagan Meadow, South Central Pinal County including Eloy/Picacho Peak State Park, Upper Santa Cruz River and Altar Valleys including Nogales, Yavapai County Mountains, Little Colorado River Valley in Navajo County, Western Mogollon Rim, Coconino Plateau, Yavapai County Valleys and Basins, Oak Creek and Sycamore Canyons, Grand Canyon Country, Little Colorado River Valley in Coconino County, Marble and Glen Canyons, Northern Gila County, White Mountains, Kaibab Plateau, Eastern Mogollon Rim, Little Colorado River Valley in Apache County

US employers expect to see biggest jump in healthcare costs in a decade in 2024

Published September 22, 2023 3:11 PM MST

Employers in the U.S. are expecting to see the largest increase in healthcare costs in a decade in 2024, according to forecasts from healthcare benefit consultants — although workers may avoid some of the increase due to the tight labor market.

Benefit consultants from Mercer, Aon and Willis Towers Watson see employers’ healthcare costs jumping by a range of 5.4% to 8.5% in 2024 because of medical inflation, high demand for expensive weight-loss drugs and the wider availability of high-priced gene therapies.

Over two-thirds of employers either don’t plan to shift any cost increases to their staff or will pass on less than the expected cost increase in 2024, according to a survey by Mercer, a unit of Marsh McLennan.

BIDEN ADMIN NAMES FIRST 10 DRUGS SUBJECT TO MEDICARE PRICE NEGOTIATION

"They don’t want to add more financial stress on employees who are also coping with inflation, especially in this time where they’re really relying on their health benefits as a way to keep employees working for them," said Beth Umland, Mercer’s director of health and benefits research.

69554910-

FILE: A doctor speaks with a patient. (Credit: Adam Berry via Getty Images)

The U.S. economy has been confronted with high consumer prices over the last year amid inflation stemming from pandemic-era spending levels and supply chain shortages. Inflation ticked up to 3.7% over the past 12 months through August, down from a 40-year high of 9.1% in June 2022.

But cost increases in the healthcare sector tend to lag economy-wide inflation due to contracts between insurers and providers such as hospitals that cover the prices for various procedures and are signed months or years in advance.

DIABETES DRUG TESTED FOR WEIGHT LOSS COULD BE GAME CHANGER

Benefit consultants help medium and large employers design their healthcare coverage plans for employees. Roughly two-thirds of U.S. workers get their benefits from such plans.

Aon projected an 8.5% increase in employer healthcare costs next year, with 1 percentage point of the total coming from weight-loss drugs alone. Sales of Novo Nordisk’s Wegovy, which is approved to treat obesity, as well as "off-label" use of similar diabetes drugs like Novo’s Ozempic and Eli Lilly’s Mounjaro for weight loss have surged amid high demand over the last year.

RELATED: Inflation is affecting parents' ability to pay for education: survey

About half a dozen gene therapies have been approved for use by U.S. regulators over the last year, most of which cost over $1 million — which the consultants noted could significantly raise costs for a company if just one employee undergoes gene therapy treatment.

All the consultants noted that employers will increasingly use artificial intelligence (AI) to reduce administrative staff expenses and added that there will be greater scrutiny of coverage for expensive therapies.

Businesses and insurers are also working to identify less expensive hospital networks for certain procedures. "Employees are given incentive that says if you go here, you pay less," said Janet Faircloth, senior vice president of Aon’s health innovation team.

Reuters contributed to this report.

Find more updates on this story at FOXBusiness.com.

HealthConsumerHealth CareU.S.News